Venmedtech, a Suzhou-based one-stop intravenous therapy product platform, has reportedly raised “tens of millions” of renminbi in a Series B+ financing round. The funding was contributed by Qiao Jing Capital and Zhuopu Venture Capital. Proceeds from the financing will be directed towards market promotion of the company’s Iliac vein stent and the research and development of various products.
Company Background and Achievements
Venmedtech, which describes itself as the first company in China focused on the treatment of peripheral venous diseases, holds marketing approvals for a range of products. These include the Iliac vein stent system, peripheral balloon catheter, peripheral vascular high-pressure balloon catheter, intravascular foreign body removal device, saphenous vein stripping catheter, and balloon pressurization device. The company has secured 40 patents in China and three abroad.
Future Development Plans
Moving forward, Venmedtech plans to enhance its intravenous interventional product pipeline, focusing on peripheral vein obstruction, stenosis, thrombosis, reflux, and other related diseases. Additionally, the company aims to expand its business scope to cover the entire process of screening, diagnosis, treatment, and prognosis. This strategic expansion is expected to solidify Venmedtech’s position as a leading provider of comprehensive solutions for peripheral venous diseases.-Fineline Info & Tech
